MedPath

Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UC

Phase 2
Terminated
Conditions
Ulcerative Colitis
Interventions
Registration Number
NCT02808390
Lead Sponsor
PPM Services S.A.
Brief Summary

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate UC.

Detailed Description

This is a Phase 2, Proof of Concept, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of 2 doses of GED-0507-34-Levo in subjects with active, mild-to-moderate Ulcerative Colitis.

The study will consist of 3 phases:

* Screening Phase - up to 4 weeks

* Double-blind Placebo-controlled Phase - Weeks 0 to 8

* Follow-up Phase - Week 9

Recruitment & Eligibility

Status
TERMINATED
Sex
All
Target Recruitment
19
Inclusion Criteria
  • Male or female aged 18 and over at the time of signing the informed consent.
  • Diagnosis of UC with a duration of at least 3 months prior to the Screening Visit.
  • MMS ≥ 4 to ≤ 8 (range: 0 - 9) prior to randomization in the study
  • Subjects are required to have a colonoscopy if one has not been performed within 12 months prior to the Screening Visit.
  • Subjects who have relapsed on maintenance therapy with doses of 5-ASA ≤ 2.4 g/day
Exclusion Criteria
  • Diagnosis of Crohn's disease, indeterminate colitis, ischemic colitis, microscopic colitis, radiation colitis, or diverticular disease-associated colitis.
  • UC restricted to the distal 15 cm or less (eg, ulcerative proctitis).
  • Subjects who have had surgery as a treatment for UC or who, in the opinion of the Investigator, are likely to require surgery for UC during the study.
  • Clinical signs suggestive of fulminant colitis or toxic megacolon.
  • Evidence of pathogenic enteric infection.
  • History of colorectal cancer or colorectal dysplasia.
  • Prior use of any TNF inhibitor (or any biologic agent).
  • Prior use of mycophenolic acid, tacrolimus, sirolimus, cyclosporine, or thalidomide.
  • Use of budesonide-MMx within the last 8 weeks.
  • Use of oral and/or IV corticosteroids within 2 weeks of the Screening Visit.
  • Use of immunosuppressants (azathioprine [AZA], 6-mercaptopurine [6-MP] or methotrexate [MTX]) within 8 weeks of the Screening Visit.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
160 mg BIDGED-0507-34-Levo 160 mgGED-0507-34-Levo 160 mg BID for 8 Weeks
PlaceboPlaceboPlacebo BID for 8 Weeks
80 mg BIDGED-0507-34-Levo 80 mgGED-0507-34-Levo 80 mg BID for 8 Weeks
Primary Outcome Measures
NameTimeMethod
Efficacy on Ulcerative Colitis Disease Activity Indexup to 8 Weeks

After 17 months, only 19 patients out of the target 207 patients, were enrolled in the study. Therefore neither descriptive nor comparative analyses were performed on outcome measures and the project in mild to moderate ulcerative colitis has been terminated.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (60)

Medical Centre "Asklepii", OOD

🇧🇬

Dupnitsa, Bulgaria

MHAT "Sv. Karidad", EAD

🇧🇬

Plovdiv, Bulgaria

Endomedix Diagnosztikai Kozpont

🇭🇺

Budapest, Hungary

Debreceni Egyetem Klinikai Kozpont

🇭🇺

Debrecen, Hungary

Bugat Pal Korhaz, Gasztroenterologia

🇭🇺

Gyongyos, Hungary

Niepubliczny Zaklad Opieki Zdrowotnej SONOMED

🇵🇱

Szczecin, Poland

Alian s.r.o.

🇸🇰

Bardejov, Slovakia

Vinnytsya RCH for Patriotic War Invalides Therapeutic Dept # 1 Vinnytsia M.I.Pyrogov NMU

🇺🇦

Vinnytsia, Ukraine

CI City Hospital #1, Dept of Surgery

🇺🇦

Zaporizhzhia, Ukraine

Polana D LLC

🇱🇻

Daugavpils, Latvia

Niepubliczny Zaklad Opieki Psychiatrycznej MENTIS

🇵🇱

Leszno, Poland

Centrum Zdrowia Matki, Dziecka i Mlodziezy

🇵🇱

Warszawa, Poland

CI of SRC Sumy RCH Dept of Gasroenterology Sumy SU MI,Chair of Internal Medicine of PGE

🇺🇦

Sumy, Ukraine

Center for Advanced Gastroenterology, PLLC

🇺🇸

Maitland, Florida, United States

Humber River Hospital

🇨🇦

Toronto, Ontario, Canada

MHAT - Pazardzhik AD

🇧🇬

Pazardzhik, Bulgaria

Envision Clinical Research, LLC

🇺🇸

Laredo, Texas, United States

Mount Sinai

🇺🇸

New York, New York, United States

BRCR Medical Center, Inc

🇺🇸

Pembroke Pines, Florida, United States

MHAT - Silistra AD

🇧🇬

Silistra, Bulgaria

IMIC, Inc

🇺🇸

Palmetto Bay, Florida, United States

Sagact, Pllc

🇺🇸

San Antonio, Texas, United States

Advanced Research Institute, Inc.

🇺🇸

New Port Richey, Florida, United States

CHU Amiens - Hopital Sud, Service d'Hépato-Gastroentérologie

🇫🇷

Amiens Cedex, France

Fondazione IRCCS Ospedale Maggiore, Policlinico Mangiagalli e Regina Elena. Dipartimento di Medicina e Specialità Mediche

🇮🇹

Milano, Italy

Policlinico Universitario Agostino Gemelli, UOC Medicina Interna e gastroenterologia - CIC

🇮🇹

Rome, Italy

Principal SMO Kft.

🇭🇺

Baja, Hungary

Health Center 4, Affiliate Diagnostic Center

🇱🇻

Riga, Latvia

Riga East Clinical University Hospital

🇱🇻

Riga, Latvia

Fondazione IRCCS Policlinico San Matteo

🇮🇹

Pavia, Italy

Azienda Ospedaliera Universitaria Policlinico Tor Vergata, Dipartimento di Medicina Interna

🇮🇹

Roma, Italy

Semmelweis Egyetem

🇭🇺

Budapest, Hungary

CI of Kyiv RC Kyiv Regional Clinical Hospital

🇺🇦

Kyiv, Ukraine

Hôpital Claude Huriez - CHU Lille, Service des maladies de l'appareil digestif

🇫🇷

Lille Cedex, France

Cabinet Médical de Gastro-entérologie Dr.Lesage

🇫🇷

Armentières, France

Cabinet Médical de Gastroentérologie Dr. Bismuth

🇫🇷

Lille, France

Cabinet Médical de Gastroentérologie Dr. Ben Ali

🇫🇷

Roubaix, France

Texas Clinical Research Institute, LLC

🇺🇸

Arlington, Texas, United States

Cook Children's Medical Center

🇺🇸

Fort Worth, Texas, United States

Clinical Applications Laboratories, Inc.

🇺🇸

San Diego, California, United States

Penn State University Milton S. Hershey Medical Center

🇺🇸

State College, Pennsylvania, United States

Cabinet Médical de Gastro-entérologie Dr.Vernier Massouille

🇫🇷

Tourcoing, France

Mazso-Pharma Kutatasfejlesztesi Kft

🇭🇺

Szeged, Hungary

Lviv Regional Clinical Hospital D.Halytskyi Lviv NMU

🇺🇦

Lviv, Ukraine

CI Zaporizhzhia Regional Clinical Hospital of ZRC

🇺🇦

Zaporizhzhia, Ukraine

MHAT "Sv. Petka" - Vidin, AD

🇧🇬

Vidin, Bulgaria

UMHAT "Sv. Georgi", EAD

🇧🇬

Plovdiv, Bulgaria

Pauls Stradins Clinical University Hospital SLLC

🇱🇻

Riga, Latvia

B+B MED, s.r.o., Gastroenterologicka ambulancia, MUDr. Brandeburova

🇸🇰

Kosice, Slovakia

Ars-Medica S.C Rybak Maria, Rybak Zbigniew

🇵🇱

Wroclaw, Poland

Gastromedic, s.r.o

🇸🇰

Nove Zamky, Slovakia

J.Seleznovs Doctor Practice

🇱🇻

Jelgava, Latvia

Korczowski Bartosz, Gabinet Lekarski, Private Pediatric Office

🇵🇱

Rzeszow, Poland

Med Center of Eurolab LLC Policlinic Outpatient Dept O.O.Bogomolets NMU

🇺🇦

Kyiv, Ukraine

Lviv Municipal City Clinical Hospital #5 Dept of Therapy D.Halytsky Lviv NMU

🇺🇦

Lviv, Ukraine

CI Odesa Regional Clinical Hospital, Center of Gastroenterology

🇺🇦

Odesa, Ukraine

A. Novak Transcarpathian Regional Clinical Hospital

🇺🇦

Uzhgorod, Ukraine

Somogy Megyei Kaposi Mor Oktato Korhaz, Gastroenterologiai Osztaly

🇭🇺

Kaposvar, Hungary

CI City Clinical Hospital #6 Dept of Gastroenterology

🇺🇦

Zaporizhzhia, Ukraine

Brandon Medical Arts Clinic

🇨🇦

Brandon, Manitoba, Canada

© Copyright 2025. All Rights Reserved by MedPath